Restarting Microsegmentation After a Clinical Network Outage
Mercy Valley Health is a 12,000-staff hospital system with 8,000 medical devices, 45 sites, 300 applications, and a single EHR vendor. After a ransomware incident, the security team launched a microsegmentation pilot in one data center covering 200 servers. The pilot blocked infusion-pump management traffic because a vendor support tunnel used an undocumented path, and a nurse-call integration showed intermittent latency. Clinical leadership paused the project. The team has 30 days to demonstrate safe progress before the next steering committee. Medical devices cannot run endpoint agents, many vendors require inbound remote support, and change windows are limited to two hours on Sunday. The CMDB lists device owners for only 60% of the 200 servers. The CISO wants a repeatable method, not a one-off exception list.
1. What discovery approach should the team use in the next 30 days before resuming enforcement?
Read the worked answer
Use passive and active discovery without blocking: span or TAP traffic at the data-center aggregation points, NetFlow/IPFIX from switches, and query the CMDB and clinical engineering database. Deploy agentless scanners only in maintenance windows and exclude life-critical VLANs. Build an application dependency map that includes clinical engineering, the EHR vendor, and vendor support tunnels. Interview device owners and vendor support desks for undocumented paths; the infusion-pump incident shows that the CMDB alone is insufficient. Classify flows by criticality: safety, clinical, business, and unknown. For unknown flows, do not block; label them and require owner attestation. Create a policy candidate set in monitor mode and compare it with observed traffic for at least two weeks.
Reasoning: microsegmentation fails in hospitals when policy is written from an incomplete asset inventory. The goal of discovery is not a perfect map but a defensible evidence base and a list of unknown flows with owners. The 30-day deliverable should be a flow inventory for the 200 servers, a top-20 unknown flow list, and a rollback plan, not a claim that segmentation is complete.
2. How should policies be designed for medical devices and vendor support tunnels?
Read the worked answer
Design around clinical workflows, not device IPs alone. Group devices by function and owner: infusion pumps, nurse call, imaging, lab, and building management. For each group, define a default-deny policy with explicit allow rules for required protocols and destinations; where the device cannot be identified strongly, use network identity plus a dedicated VLAN and a policy enforcement point in front of the management plane. Separate clinical traffic from management traffic: a pump may need to talk to its management server, but a vendor laptop should not reach the pump VLAN directly. For vendor support, require a broker or jump host that terminates the vendor session, enforces MFA, records the session, and opens only the approved destination for a time window. The vendor should never receive a standing tunnel.
Use two-hour Sunday change windows for enforcement, with a canary group of non-critical devices first. Reasoning: medical devices often have weak identity and long lifecycles, so the PEP must compensate with network and session controls. Safety requires that policy changes be reversible and tested with clinical staff. The nurse-call latency issue indicates that QoS and flow symmetry must be part of the policy test, not just allow/deny.
3. What rollout, rollback, and success metrics should the CISO present to the steering committee?
Read the worked answer
Present a staged rollout: monitor mode for all 200 servers for two weeks; enforce for a canary of 10 non-critical servers; then expand by clinical service line, with a go/no-go gate for each. Rollback should be a pre-built policy exception that restores the prior VLAN path within 15 minutes, owned by the network team and tested before each wave.
Success metrics: percentage of flows with a named owner, number of unknown flows reduced, number of standing vendor tunnels removed, policy exceptions with expiry dates, and clinical incident rate during change windows. Also track leading indicators: time to approve a new flow, time to roll back, and percentage of policies in monitor mode versus enforce. Reasoning: the steering committee needs to see safety and control, not just coverage. A 100% segmentation claim after a paused pilot would be less credible than a canary with zero clinical impact and a tested rollback. The CISO should explicitly define what would cause a pause: any safety-related incident, unexplained latency above an agreed threshold, or an unknown flow to a life-critical device. This makes the risk trade-off visible and keeps clinical leadership engaged.